Bruker Introduces maXis HD Ultra-High Resolution QTOF
At the 12th Human Proteome Organization World Congress (www.hupo.org/2013), Bruker completed its series of High-Definition (HD) QTOF systems introductions with the launch of its new flagship maXis HD ultra-high resolution (UHR) QTOF mass spectrometer. With its best-in-class full sensitivity resolution (FSR) greater than 75,000, the new maXis HD is ideally suited for top-down proteomic analyses and the characterisation of biopharmaceuticals.
The novel maXis HD features a new High-Definition Collision (HDC) cell which enables its record-breaking full sensitivity mass resolution, as well as accurate mass capabilities well beyond all competing QTOF As a result of its extreme sensitivity broad mass-transfer ion optics and the fastest available 50 Gbit/s sampling technology, a dynamic range of five orders of magnitude is achieved in one second of LC time. High dynamic range at high speed is a prerequisite for high-resolution detection of low-abundance compounds in sharp UHPLC peaks and permits direct identification and quantitation without re-runs.
The maXis HD offers break-through analytical performance for applications in top-down proteomics and in biopharmaceutical compound analysis, and the instrument excels in the analysis of intact proteins and antibodies. For antibody subunits, it can provide unprecedented insight into antibody structures via its ultra-high resolution at high mass with baseline discrimination of isotope envelopes at excellent mass accuracy.
The maXis HD also delivers a new confidence level in the fast, high-resolution, accurate mass screening, identification and quantification of small molecules. The novel HDC cell and HD detection technology translate directly into enhanced dynamic range and extreme sensitivity down to very low masses at UHPLC speed, a precondition for one-shot plug and play acquisitions in multi-target applications. The recording-breaking full sensitivity resolution in combination with the Bruker proprietary, real-time SmartFormula 3D software makes the maXis HD the tool of choice for true unknown screening and the ab initio determination of elemental composition at UHPLC speed and throughput.
Dr Michael Schubert, President of the Bruker Daltonics Life-Science & Clinical Division, stated: “With these performance features we believe that the new maXis HD delivers the fastest time-to-success for customers across a broad applications portfolio, covering small molecule identification and characterisation; food, forensic and environmental screening; metabolomics; as well as top-down proteomics and antibody analysis."
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...